Abstract Guidelines
The Nordic HIV & Virology Conference invites you to submit abstracts reporting new research or developing information on HIV/AIDS, hepatitis and related conditions. We welcome abstracts presenting unpublished studies, case reports, systematic reviews and scientific approaches on methodology and quality improvement. Studies presented in part on other meetings and recently published data can also be considered. The Scientific Program Committee will select abstracts on the basis of their medical significance, timeliness, the quality of the data and methodology, and adherence to specific format requirements and other criteria described herein. A few abstracts will be selected for oral presentations and the remaining for posters.

Required Elements
Each abstract must include the following:
Title. The title should appear in boldface at the top. It should be concise (no more than 130 characters, not including spaces) and unambiguously represent the subject of the abstract.
Authors’ names: These names should appear in below the title. They should be separated by commas, with first names first followed by middle initials and last name only (no titles or degrees). The presenting author should be the first name added in the authors list. Add affiliations, use superscripts to identify the author and the affiliation (for example: Name A¹, Name B², University X¹, University Y²). List no more than 10 authors on each abstract.
Background: This section briefly presents the hypothesis of the abstract or encapsulates the subject under study.
Methods: This section details the experimental methods and processes employed in the study.
Results: This section describes the precise findings of the study. Promises of results “to be determined” are not acceptable.
Conclusions: This section describes logically sound conclusions and reliable inferences from the results.

Abstract Length
The titles of abstracts should not exceed 130 characters (not including spaces). The body text should not exceed 3000 characters (not including spaces). Embedded images (tables, figures, etc) will be counted as 250 characters.

Abstract timeline
Abstract submission opens
2022-xx-xx
Last day for submitting abstracts
2022-xx-xx
Decisions for abstracts emailed
2022-xx-xx

Instructions for posters
Posterboards will have a display area 150 cm wide x 100 cm high. Your poster must fit within these dimensions. Posters will be fixed to boards using push pins supplied onsite. The posters should be up for the entire session and presenters are encouraged to be at their posters during the poster mingle on Wednesday, starting from 18.45 and one break according to below schedule:
P1-P12 Wednesday 16.00-16.30
P13-P23 Thursday 10.30-11.00
P24-P34 Thursday 16.00-16.20
P35-P42 Friday 10.10-10.45

Nordic HIV & Virology Abstract Award 2022
The two best posters, one within HIV and one within Hepatitis, will be selected by the Scientific Program Committee and rewarded with a Research Grant of 1250 Euro each; the ”Nordic HIV & Virology 2022 Abstract Award”.

Abstract archive

2019
Winners – Abstract award, selected by the Scientific Program Committee.
Activated and exhausted CD8 T-cells differentiate aviremic HIV-2 infected from seronegative individuals
Lydia Scharf, Christina B Pedersen, Jakob Lopakto Lindman, Lars R Olsen, Sten Wilhelmson, Fredrik Månsson, Joakim Esbjörnsson, Antonio Biague, Patrik Medstrand, Hans Norrgren, Marianne Jansson*, Annika C Karlsson* and the SWEGUB GORE Group
*Contributed equally to this work

A long-term study of 337 hepatitis D virus (HDV) and hepatitis B virus co-infected patients: the impact of HDV viremia on liver-related outcomes
Habiba Kamal, Gabriel Westman, Karolin Falconer, Ann-Sofi Duberg, Ola Weiland, Susanna Haverinen, Rune Wejstål, Tony Carlsson, Christian Kampmann, Simon Larsson, Per Björkman, Anders Nystedt, Kristina Cardell, Stefan Svensson, Stephan Stenmark, Heiner Wedemeyer, Soo Aleman

All abstracts from 2019

2018
Winning abstracts
The microbial metabolite TMAO in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages
Catharina Missailidis, Göran Bratt, Ujjwal Neogi, Peter Stenvinkel, MariusTrøseid, Piotr Nowak*, Peter Bergman*
*Contributed equally to this work

A DNA-based immunotherapy induces receptor-blocking antibodies that can neutralize HBV in humanized mice
Panagiota Maravelia, Lars Frelin, Neetu Jagya, Lieven Verhoye, Georg Verch, Yi Ni, Gustaf Ahlén, Stephan Urban, Philip Meuleman, Matti Sällberg

All abstracts from 2018

2017
Winning abstract
Cervicovaginal inflammation is strongly modulated by cyclic changes in sex hormones and amplified by the microbiome
Frideborg Bradley*, Kenzie Birse*, Klara Hasselrot, Laura Romas, Andrea Introini, Hugo Wefer, Maike Seifert, Lars Engstrand, Annelie Tjernlund, Kristina Broliden, Adam Burgener
*Contributed equally to this work

2016
Winning abstract
A Longitudinal Study on the Dynamics of Plasma Neutralising Antibodies and Determinants in HIV-2 Infection
Hans Norrgren, Gülşen Özkaya Şahin, Sara Karlson, Antonio Biague, Fredrik Månsson, Marianne Jansson and Sweden-Guinea-Bissau Cohort Research Group

2015
Winning abstract
Sustained expression of the inhibitory receptor TIGIT is linked to CD8 T cell exhaustion despite successful ART.
Johanna Tauriainen, Noor Salam, Bo Hejdeman, Anders Sönnerborg, Hans-Gustaf Ljunggren, Frederick M Hecht, Steven G Deeks, Michael R Betts, Marcus Buggert, Annika C Karlsson.

2014
Winning abstract
High incidence of high grade cervical neoplasia among women with HIV in Sweden
Christina Carlander, Anders Sönnerborg, Veronica Svedhem-Johansson, Katarina Westling, Kristina Elfgren, Pär Sparen